Sara Majocchi
Discovery Program Leader Light Chain Bioscience
Sara Majocchi is a Discovery Program Leader at Light Chain Bioscience, Geneva, Switzerland. She obtained her Master’s degree in biotechnology from the École Supérieure de Biotechnologie de Strasbourg, Louis Pasteur University, France and her PhD in Life Science from the University of Lausanne, Switzerland. After graduation, Sara joined the Research Department of Light Chain Bioscience where her focus was on developing mouse models to support the preclinical development of the first bispecific therapeutic programs targeting CD47.  Since 2018, she has led the discovery of therapeutic bispecific antibodies, guiding programs from early discovery through clinical lead selection, with several candidates now advancing in clinical evaluation.
Seminars
- The use of molecules capable of activating the immune system by targeting costimulatory signals on T cells has not been fully explored yet
- NI-4101 is a FcRH5xCD28 bispecific antibody which has the potential to expand the number of patients who benefit from TCE-based therapies, possibly leading to deeper and more durable responses
- NI-3201, a PD-L1xCD28 bispecific antibody, additionally blocks the PD-L1/PD-1 immune checkpoint pathway, thus overcoming two major immune suppression mechanisms at once
